Labopharm raises $22 million for product launch and R&D

Guest Contributor
July 7, 2003

Labopharm Inc is set to complete a $22-million share issue on July 15 to support the commercial launch of its tramadol analgesic and advance development of a new program in the Laval PQ-based firm’s pipeline. The financing is a bought deal by a syndicate of underwriters led by National Bank Financial Inc and including RBC Dominion Securities Inc, Research Capital Corp, CIBC World Markets Inc, Canacord Capital Corp, and Orion Securities Inc (formerly Yorkton Securities Inc). Labopharm is developing a series of drugs based on Contramid, its controlled release technology. Its pipeline of in-house and partnered programs includes four products in clinical trials and four now in preclinical development. The offering will also be used for working capital and general corporate purposes....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.